Goldman Sachs Group Inc Crispr Therapeutics Ag Put Options Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $1.31 Million - $1.92 Million	-21,600 Reduced 74.23%	7,500 $511,000
Q4 2023 Feb 13, 2024	SELL	$38.62 - $72.18 $1.62 Million - $3.02 Million	-41,900 Reduced 59.01%	29,100 $1.82 Million
Q3 2023 May 14, 2024	BUY	$45.39 - $59.0 $1.9 Million - $2.47 Million	41,900 Added 143.99%	71,000 $3.22 Million
Q1 2023 May 14, 2024	SELL	$41.0 - $56.12 $3.92 Million - $5.37 Million	-95,700 Reduced 57.41%	71,000 $3.21 Million
Q1 2023 May 11, 2023	SELL	$41.0 - $56.12 $3.92 Million - $5.37 Million	-95,700 Reduced 57.41%	71,000 $3.21 Million
Q4 2022 May 14, 2024	SELL	$39.19 - $65.67 $6.34 Million - $10.6 Million	-161,800 Reduced 49.25%	166,700 $6.78 Million
Q4 2022 Feb 13, 2023	SELL	$39.19 - $65.67 $6.34 Million - $10.6 Million	-161,800 Reduced 49.25%	166,700 $6.78 Million
Q3 2022 May 14, 2024	BUY	$61.1 - $83.78 $11.3 Million - $15.5 Million	185,000 Added 128.92%	328,500 $21.5 Million
Q3 2022 Nov 10, 2022	BUY	$61.1 - $83.78 $11.3 Million - $15.5 Million	185,000 Added 128.92%	328,500 $21.5 Million
Q2 2022 May 14, 2024	BUY	$43.23 - $73.83 $4.95 Million - $8.45 Million	114,400 Added 393.13%	143,500 $8.72 Million
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $6.2 Million - $10.6 Million	143,500 New	143,500 $8.72 Million

503

57M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.28B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.